Induced pluripotent stem cell (iPSC) therapy represents one of the most promising disease-modifying approaches for Parkinson's disease (PD). This therapeutic strategy aims to replace the dopaminergic neurons lost in Parkinson's disease by transplanting neurons derived from pluripotent stem cells into the substantia nigra pars compacta—the brain region where these neurons degenerate.
Unlike symptomatic treatments that only manage motor symptoms (such as levodopa, dopamine agonists, or MAO-B inhibitors), iPSC cell therapy has the potential to halt or reverse disease progression by restoring the lost neuronal population and reconstituting dopaminergic signaling in the nigrostriatal pathway.
iPSC-derived dopaminergic neuron therapy works through several key mechanisms:
- Neuronal Replacement: Transplanted iPSC-derived dopaminergic neurons replace dead or dysfunctional neurons in the substantia nigra
- Dopamine Production: These neurons synthesize and release dopamine, restoring neurotransmitter levels in the striatum
- Circuit Integration: Neuronal axons grow and form synaptic connections with host neurons in the basal ganglia circuit
- Trophic Support: Transplanted neurons secrete neurotrophic factors that support remaining endogenous neurons
The primary target for transplantation is the putamen, a structure in the basal ganglia that receives dopaminergic input from the substantia nigra. The putamen is the main region where dopamine deficiency manifests in PD patients.
¶ Clinical Trial Landscape
| Company |
Product |
Cell Source |
Phase |
Trial ID |
Status |
| UC San Diego |
CT1-DAP001 |
iPSC-derived dopaminergic progenitors |
Phase 1 |
NCT06482268 |
Recruiting |
| BlueRock Therapeutics |
BRT-DA01 |
hESC-derived DA neurons |
Phase 1 |
NCT04802733 |
Active |
| Aspen Neuroscience |
ANPD001 |
Autologous iPSC-derived DA neurons |
Phase 1/2 |
NCT05796382 |
Recruiting |
| Kyoto University |
iPSC-derived DA neurons |
Autologous iPSCs |
Phase 1/2 |
— |
Active |
| Lundbeck/Oxford |
SC2587 |
ESC-derived DA neurons |
Phase 1/2 |
— |
Active |
The CT1-DAP001 trial is a Phase 1 study of human iPS cell-derived dopaminergic progenitors for Parkinson's disease, sponsored by UC San Diego.
Trial Details:
- Design: First-in-human, Phase 1 study
- Sponsor: University of California San Diego
- Cell Source: Human iPSC-derived dopaminergic progenitors
- Trial ID: NCT06482268
- Status: Recruiting
This trial represents an important addition to the iPSC cell therapy landscape for PD, contributing to the growing body of evidence for cell replacement therapy approaches.
BlueRock Therapeutics, a Bayer AG company, is conducting the STEM-PD trial—the first Phase 1 clinical trial of pluripotent stem cell-derived dopaminergic neurons for Parkinson's disease.
Trial Details:
- Design: Open-label, dose-escalation study
- Patients: Adults with advanced PD (Hoehn & Yahr stage 2.5-3)
- Dosing: Single surgical implantation of ~70 million cells
- Delivery: Stereotactic injection into bilateral putamen
- Primary Endpoints: Safety and tolerability at 12 months
- Secondary Endpoints: Motor function (MDS-UPDRS Part III), PET imaging of dopamine function
Cell Manufacturing:
- Cell source: Human embryonic stem cells (hESCs)
- Differentiation: Directed differentiation to midbrain dopaminergic neurons
- Quality control: Comprehensive potency assays, sterility testing
- Allogeneic: Off-the-shelf, HLA-matched cells
Aspen Neuroscience is developing the first autologous (patient-specific) iPSC therapy for PD.
Trial Details:
- Design: First-in-human, patient-specific therapy
- Approach: Patient's own skin or blood cells reprogrammed to iPSCs, then differentiated
- Advantage: No immunosuppression required
- Status: Phase 1/2 trial enrolling
Autologous Approach:
- Patient-derived iPSCs eliminate immune rejection risk
- Requires ~6-9 months for cell manufacturing per patient
- CRISPR gene editing possible to correct genetic mutations
- Higher cost and longer production time than allogeneic approaches
The Kyoto University iPSC program, led by Dr. Jun Takahashi, represents the pioneering clinical effort in this field. Building on the work of Shinya Yamanaka (who won the Nobel Prize for discovering iPSC technology), this program has advanced autologous iPSC therapy for PD.
Key Features:
- Autologous iPSCs derived from patient's own cells
- First clinical trial initiated in Japan (2018)
- Published safety data from initial patients
- Demonstrated long-term cell survival in human brain
- Somatic Cell Collection: Patient's skin fibroblasts or blood cells are collected
- Reprogramming: Cells are transfected with Yamanaka factors (OCT4, SOX2, KLF4, c-MYC)
- iPSC Colony Selection: Individual colonies are picked and expanded
- Characterization: Pluripotency confirmed via marker expression and teratoma formation
The differentiation protocol follows stages that recapitulate human brain development:
flowchart TD
A["iPSCs"] --> B["Definitive Endoderm"]
B --> C["Neural Rosette"]
C --> D["Floor Plate"]
D --> E["Midbrain Precursors"]
E --> F["Dopaaminergic Neurons"]
F --> G["Quality Control"]
G --> H["Clinical Grade Cells"]
**Key Protocols:**
- Floor Plate Induction: Using SHH and WNT signaling modulation
- Midbrain Patterning: Specification to A9 subtype (substantia nigra neurons)
- Neuronal Maturation: Maturation to post-mitotic dopaminergic neurons
- Purification: Enrichment for TH-positive (tyrosine hydroxylase) neurons
Challenges:
- Scalable production while maintaining potency
- Consistent differentiation efficiency
- Cryopreservation and thawing viability
- Quality control at each stage
Solutions:
- Closed, automated bioreactor systems
- Master cell bank approach
- Defined media formulations
- Standardized potency assays
The standard delivery method for dopaminergic neuron transplantation is stereotactic neurosurgery:
-
Preoperative Planning:
- High-resolution MRI for target identification
- Trajectory planning to avoid blood vessels
- Calculation of target coordinates
-
Surgical Procedure:
- Patient under local or general anesthesia
- Head fixed in stereotactic frame
- Small burr hole made in skull
- Cannula inserted to target coordinates
-
Cell Injection:
- Cells delivered in suspension
- Multiple injection tracks in putamen
- Slow injection rate to prevent reflux
- Bilateral implantation (both hemispheres)
- Targeting Precision: Submillimeter accuracy required
- Cell Survival: Maximizing survival after transplantation
- Immune Response: Managing host immune response to foreign cells
- Distribution: Achieving uniform cell distribution in target region
Kyoto University (Autologous iPSC):
- First patient treated in 2018
- No serious adverse events reported
- Preliminary evidence of motor symptom improvement
- PET imaging showed surviving transplanted cells
BlueRock STEM-PD (Allogeneic hESC):
- Primary endpoint: Safety and tolerability
- Early data showed cells survived in all patients
- Some patients showed improvement in OFF-medication UPDRS scores
- No tumor formation detected
In non-human primate models of PD:
- Transplanted neurons survived for >2 years
- Axonal outgrowth to striatum confirmed
- Functional recovery in behavioral tests
- No tumor formation in long-term studies
| Factor |
Autologous (Aspen) |
Allogeneic (BlueRock) |
| Immune rejection |
Minimal |
Requires immunosuppression |
| Manufacturing time |
6-9 months |
Off-the-shelf |
| Cost per dose |
Very high |
Lower per dose |
| Gene editing |
Possible |
Limited |
| Scalability |
Challenging |
Easier |
| Factor |
iPSC-derived |
ESC-derived |
| Ethical concerns |
Minimal |
Some |
| Patient-specific |
Yes |
No |
| Tumor risk |
Lower |
Lower |
| Autologous possible |
Yes |
No |
- Tumor Formation: Undifferentiated pluripotent cells could form teratomas
- Immune Rejection: Host immune response to transplanted cells
- Dyskinesias: Abnormal involuntary movements from over-dopamination
- Infection: Surgical site infection or meningitis
- Hemorrhage: Intracranial bleeding from surgery
- Comprehensive quality control to remove undifferentiated cells
- HLA matching and immunosuppression for allogeneic cells
- Careful dose titration
- Sterile surgical techniques
- Long-term monitoring
¶ Investment Landscape
The iPSC cell therapy field for Parkinson's has attracted significant investment:
| Company |
Funding |
Focus |
| BlueRock Therapeutics |
$1B+ (Bayer) |
Allogeneic hESC therapy |
| Aspen Neuroscience |
$220M+ |
Autologous iPSC therapy |
| Cynata Therapeutics |
Public (ASX:CYP) |
MSC-based therapy |
- Lead program: BRT-DA01 (STEM-PD trial)
- Allogeneic hESC-derived neurons
- Company page
- Lead program: ANPD001 (autologous)
- Patient-specific iPSC approach
- Company page
- Platform: Cymerus™ iPSC technology
- iPSC-derived mesenchymal stem cells
- Company page
- Program: SC2587
- ESC-derived dopaminergic neurons
- Phase 1/2 trial in Europe
- Gene-Enhanced Cells: Engineering cells to express neurotrophic factors (GDNF, BDNF)
- Encapsulated Cell Therapy: Using encapsulated cell devices for controlled factor delivery
- Combination Approaches: Cell therapy combined with small molecules or immunomodulation
- Induced Neurons (iN): Direct conversion of astrocytes to neurons
- Improving cell survival and integration
- Reducing manufacturing costs and time
- Defining patient selection criteria
- Establishing long-term efficacy
- Achieving consistent clinical results